BioSpace News Archive

Ginkgo Bioworks announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency to achieve DARPA’s objectives under its new Ice Control for cold Environments program.

Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).

IMUNON, Inc. reported financial results for the year ended December 31, 2023.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.

Sofwave Medical Ltd (TASE: SOFW) today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will provide a corporate update and participate in one-on-one investor meetings at the Needham 23rd Annual Healthcare Conference, to be held virtually from April 8-11, 2024.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Tevogen Bio Holdings has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology’s Annual Scientific Session (ACC.24).

TransCode Therapeutics, Inc. announced that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.

CervoMed Inc. announced that it has entered into a definitive securities purchase agreement for a private placement to sell an aggregate of 2,532,285 units, each Unit comprised of one share of its common stock or one pre-funded warrant to purchase shares of its common stock, and in each case, one Series A warrant to purchase shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement.